Skip to main content
. 2014 Jun 27;9(6):e100562. doi: 10.1371/journal.pone.0100562

Figure 3. Effect of pharmacologic treatments on serum level of insulin growth factor-I (IFG-I) and vascular endothelial growth factor (VEGF) in experimental groups.

Figure 3

Effect of oxaliplatin and/or metformin (100 or 200 mg/kg) on serum IGF-I (panel A) and serum VEGF (panel B). Mice [except saline group] were injected with 1,2-dimethylhydrazine (DMH) weekly for 15 week to induce colon cancer then treated with oxaliplatin and/or metformin (100 or 200 mg/kg) for 4 weeks. DMH: 1,2-dimethylhydrazine, IGF-I: insulin growth factor-I, VEGF: vascular endothelial growth factor. Results are expressed as mean ± S.E.M. and analyzed using two-way ANOVA followed by Tukey's post-hoc test at P<0.05.*Significantly different from saline group. #Significantly different from DMH group. $Significantly different from oxaliplatin group. ≠Significantly different from metformin (100 mg/kg) group. ×Significantly different from metformin (200 mg/kg), n = 5–6.